374 related articles for article (PubMed ID: 15896094)
41. Quality-adjusted life-years lack quality in pediatric care: a critical review of published cost-utility studies in child health.
Griebsch I; Coast J; Brown J
Pediatrics; 2005 May; 115(5):e600-14. PubMed ID: 15867026
[TBL] [Abstract][Full Text] [Related]
42. Valuing QALY gains by applying a societal perspective.
Bobinac A; van Exel NJ; Rutten FF; Brouwer WB
Health Econ; 2013 Oct; 22(10):1272-81. PubMed ID: 23080321
[TBL] [Abstract][Full Text] [Related]
43. Willingness to pay for one quality-adjusted life year in Iran.
Moradi N; Rashidian A; Nosratnejad S; Olyaeemanesh A; Zanganeh M; Zarei L
Cost Eff Resour Alloc; 2019; 17():4. PubMed ID: 30867654
[TBL] [Abstract][Full Text] [Related]
44. Monetary value of health-a practical decision-making framework combining equity considerations and WTP.
Ribarić E; Velić I; Bobinac A
Eur J Health Econ; 2024 May; ():. PubMed ID: 38769211
[TBL] [Abstract][Full Text] [Related]
45. Life satisfaction, QALYs, and the monetary value of health.
Huang L; Frijters P; Dalziel K; Clarke P
Soc Sci Med; 2018 Aug; 211():131-136. PubMed ID: 29935403
[TBL] [Abstract][Full Text] [Related]
46. Assessing preferences for prevention versus treatment using willingness to pay.
Corso PS; Hammitt JK; Graham JD; Dicker RC; Goldie SJ
Med Decis Making; 2002; 22(5 Suppl):S92-101. PubMed ID: 12369235
[TBL] [Abstract][Full Text] [Related]
47. An exploratory study to estimate cost-effectiveness threshold value for life saving treatments in western Iran.
Moradi N; Woldemichael A; Malekian P; Rotvandi DM; Rezaei S
Cost Eff Resour Alloc; 2020; 18():47. PubMed ID: 33110399
[TBL] [Abstract][Full Text] [Related]
48. Exploring a new method for deriving the monetary value of a QALY.
Tilling C; Krol M; Attema AE; Tsuchiya A; Brazier J; van Exel J; Brouwer W
Eur J Health Econ; 2016 Sep; 17(7):801-9. PubMed ID: 26289341
[TBL] [Abstract][Full Text] [Related]
49. Valuing the benefits and costs of health care programmes: where's the 'extra' in extra-welfarism?
Birch S; Donaldson C
Soc Sci Med; 2003 Mar; 56(5):1121-33. PubMed ID: 12593883
[TBL] [Abstract][Full Text] [Related]
50. Can we estimate the 'social' value of a QALY? Four core issues to resolve.
Smith RD; Richardson J
Health Policy; 2005 Sep; 74(1):77-84. PubMed ID: 16098414
[TBL] [Abstract][Full Text] [Related]
51. Analyzing cost-effectiveness of ulnar and median nerve transfers to regain forearm flexion.
Wali AR; Park CC; Brown JM; Mandeville R
Neurosurg Focus; 2017 Mar; 42(3):E11. PubMed ID: 28245686
[TBL] [Abstract][Full Text] [Related]
52. Valuing QALYs in Relation to Equity Considerations Using a Discrete Choice Experiment.
van de Wetering L; van Exel J; Bobinac A; Brouwer WB
Pharmacoeconomics; 2015 Dec; 33(12):1289-300. PubMed ID: 26232199
[TBL] [Abstract][Full Text] [Related]
53. Willingness to pay for a quality-adjusted life year: a systematic review with meta-regression.
Kouakou CRC; Poder TG
Eur J Health Econ; 2022 Mar; 23(2):277-299. PubMed ID: 34417905
[TBL] [Abstract][Full Text] [Related]
54. Results of a model analysis to estimate cost utility and value of information for intravenous immunoglobulin in Canadian adults with chronic immune thrombocytopenic purpura.
Xie F; Blackhouse G; Assasi N; Campbell K; Levin M; Bowen J; Tarride JE; Pi D; Goeree R
Clin Ther; 2009 May; 31(5):1082-91; discussion 1066-8. PubMed ID: 19539109
[TBL] [Abstract][Full Text] [Related]
55. Evaluating discrete choice experiment willingness to pay [DCE-WTP] analysis and relative social willingness to pay [RS-WTP] analysis in a health technology assessment of a treatment for an ultra-rare childhood disease [CLN2].
Moro D; Schlander M; Telser H; Sola-Morales O; Clark MD; Olaye A; Camp C; Jain M; Butt T; Bakshi S
Expert Rev Pharmacoecon Outcomes Res; 2022 Jun; 22(4):581-598. PubMed ID: 34877915
[TBL] [Abstract][Full Text] [Related]
56. Is there a kink in consumers' threshold value for cost-effectiveness in health care?
O'Brien BJ; Gertsen K; Willan AR; Faulkner LA
Health Econ; 2002 Mar; 11(2):175-80. PubMed ID: 11921315
[TBL] [Abstract][Full Text] [Related]
57. Estimating the range of incremental cost-effectiveness thresholds for healthcare based on willingness to pay and GDP per capita: A systematic review.
Iino H; Hashiguchi M; Hori S
PLoS One; 2022; 17(4):e0266934. PubMed ID: 35421181
[TBL] [Abstract][Full Text] [Related]
58. Willingness to pay and the valuation of programmes for the prevention and control of influenza.
Birch S; Gafni A; O'Brien B
Pharmacoeconomics; 1999; 16 Suppl 1():55-61. PubMed ID: 10623377
[TBL] [Abstract][Full Text] [Related]
59. GET MORE, PAY MORE? An elaborate test of construct validity of willingness to pay per QALY estimates obtained through contingent valuation.
Bobinac A; van Exel NJ; Rutten FF; Brouwer WB
J Health Econ; 2012 Jan; 31(1):158-68. PubMed ID: 22018622
[TBL] [Abstract][Full Text] [Related]
60. Comparative effectiveness and cost-effectiveness of the implantable miniature telescope.
Brown GC; Brown MM; Lieske HB; Lieske PA; Brown KS; Lane SS
Ophthalmology; 2011 Sep; 118(9):1834-43. PubMed ID: 21723614
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
